Get the Stockscreener App
45.47
3.44%
-1.62
After Hours:
45.47
Merus N V stock is traded at $45.47, with a volume of 815.97K.
It is down -3.44% in the last 24 hours and up +14.79% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$47.09
Open:
$47.24
24h Volume:
815.97K
Relative Volume:
1.35
Market Cap:
$3.15B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-11.51
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
-2.74%
1M Performance:
+14.79%
6M Performance:
-9.91%
1Y Performance:
-12.25%
1-Day Range:
$45.00
$47.43
1-Week Range:
$43.90
$47.67
52-Week Range:
$37.77
$61.61
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
45.47 | 3.15B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Piper Sandler | Overweight |
| Feb-07-25 | Initiated | Wells Fargo | Overweight |
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
Merus stock holds Buy rating and $85 target from H.C. Wainwright - Investing.com
Merus’ (MRUS) Outperform Rating Reiterated at William Blair - Defense World
Needham & Company LLC Cuts Merus (NASDAQ:MRUS) Price Target to $83.00 - Defense World
Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts - Simply Wall St
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates - MSN
Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS) - Yahoo Finance
Merus (NASDAQ:MRUS) Posts Quarterly Earnings Results, Beats Estimates By $0.48 EPS - MarketBeat
BMO Capital lifts Merus stock target to $96, maintains Outperform By Investing.com - Investing.com South Africa
BMO Capital lifts Merus stock target to $96, maintains Outperform - Investing.com
Merus Shares Soar Amid Breakthrough Therapy Hopes - TipRanks
Merus NV reports results for the quarter ended December 31Earnings Summary - TradingView
Merus N.V. Updates on Petosemtamab Trials and Financial Outlook for 2025 and Beyond - Nasdaq
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update - GlobeNewswire
Merus Secures FDA Approval for Cancer Drug With $724M War Chest to Fund Operations Through 2028 - StockTitan
Merus N.V. SEC 10-K Report - TradingView
Merus N.V. to Host Earnings Call - ACCESS Newswire
Investor Network: Merus N.V. to Host Earnings Call - ACCESS Newswire
State of New Jersey Common Pension Fund D Buys 10,842 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Impax Asset Management Group plc Invests $7.57 Million in Merus (NASDAQ:MRUS) - MarketBeat
Merus to Present at Upcoming Investor Conferences - GlobeNewswire
Clinical-Stage Oncology Innovator Merus Schedules Two Major Investor Presentations - StockTitan
Merus (MRUS) to Release Quarterly Earnings on Wednesday - MarketBeat
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN
TimesSquare Capital Management LLC Purchases 58,760 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Merus Stock Soars on Cancer Treatment Breakthrough - TipRanks
La FDA américaine a accordé le statut de thérapie innovante au pétosemtamab dans le carcinome épidermoïde de la tête et du cou positif PD-L1 positif en 1re ligne - GlobeNewswire Inc.
Merus Shares Are Up Today: What's Going On?Merus (NASDAQ:MRUS) - Benzinga
Merus Stock Surges on Breakthrough Therapy News - TipRanks
Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab -February 18, 2025 at 09:00 am EST - Marketscreener.com
Objective long/short (MRUS) Report - Stock Traders Daily
Petosemtamab granted Breakthrough Therapy designation by - GlobeNewswire
Revolutionary Cancer Treatment: 67% Response Rate Earns FDA Breakthrough Status for Head & Neck Cancer Drug - StockTitan
Merus N.V.'s SWOT analysis: biotech firm's stock poised for growth amid clinical trials - Investing.com India
Merus (NASDAQ:MRUS) Now Covered by Analysts at Piper Sandler - MarketBeat
BMO Capital Maintains Merus N.V. (MRUS) Outperform Recommendation - MSN
Guggenheim Reaffirms Buy Rating for Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Receives Average Rating of “Buy” from Analysts - Defense World
Piper Sandler sets $84 target on Merus stock, cites drug potential - Investing.com Australia
FY2024 Earnings Forecast for Merus Issued By Leerink Partnrs - MarketBeat
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit -February 13, 2025 at 08:01 am EST - Marketscreener.com
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - The Manila Times
Revolutionary Cancer Treatment Updates: Merus CEO Takes Center Stage at Major Oncology Summit - StockTitan
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga India
Piper Sandler Initiates Merus at Overweight With $84 Price Target -February 13, 2025 at 07:36 am EST - Marketscreener.com
Piper Sandler sets $84 target on Merus stock, cites drug potential By Investing.com - Investing.com South Africa
What is Leerink Partnrs’ Estimate for Merus FY2024 Earnings? - Defense World
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merus N V Stock (MRUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shuman Harry | VP Controller, PAO |
Aug 21 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Aug 20 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Option Exercise |
17.94 |
10,000 |
179,400 |
10,000 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Sale |
60.00 |
10,000 |
600,000 |
0 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Option Exercise |
24.36 |
62,000 |
1,510,280 |
62,000 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Sale |
56.52 |
62,000 |
3,504,178 |
0 |
| Shuman Harry | VP Controller, PAO |
Jun 12 '24 |
Sale |
57.84 |
7,300 |
422,232 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 10 '24 |
Sale |
53.22 |
1,000 |
53,224 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 04 '24 |
Sale |
52.89 |
6,000 |
317,354 |
7,002 |
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):